Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study

Yehuda Carmeli*, Jon Armstrong, Peter J. Laud, Paul Newell, Greg Stone, Angela Wardman, Leanne B. Gasink

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

342 Scopus citations

Fingerprint

Dive into the research topics of 'Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science